Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion.  Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.

“That’s a 4 percent and 6 percent when you account for one-offs,” said Richard Saynor, CEO, Sandoz, in a video shared on the company’s LinkedIn page.

Profitability also improved during the period, with the core EBITDA margin rising to 20 percent.

While the company’s base generics business continued its growth, biosimilar sales saw a 17 percent increase, supported by three product launches across the US and Europe in the first half of the year.

Looking ahead, Sandoz expects to maintain this strong momentum into the second half of the year, supported by more planned launches. The company has confirmed its full-year guidance accordingly.

“Looking further ahead, we’re determined to retain our leadership in the rapidly expanding biosimilar market and we’re investing to succeed,” Saynor said.

On July 1, Sandoz broke ground on a new facility in Slovenia to further expand its European biosimilar hub. Later in the month, on July 30, the company announced its proposed acquisition of Just-Evoctec Biologics’ activities in Toulouse.  

“This would support our strategy of reinforcing in-house biosimilar capabilities while creating additional strategic flexibility,” Saynor noted.

He emphasised that Sandoz is positioning itself to make the most unprecedented 300 billion of biosimilar Loss of Exclusivity (LoE) opportunity that we see over the next decade.

“We’re also continuing to play our part in leading in biosimilar science, as we streamline clinical development programs from two more biosimilars, making a total of three so far this year,” he added.  

Sandoz believes that reducing development costs and timelines for future biosimilar programs is critical, as that will ultimately result in even more patients being able to access these incredible medicines.   

At the same time, the company remains focused on the large opportunities within its base generics business, including the rapidly emerging markets for GLP-1 weight loss and diabetes medication.

“Generics still present 70 percent of our total business, and it's our commitment to both generic and biosimilar leadership that makes Sandoz so unique,” said Saynor.

He concluded by thanking all Sandoz stakeholders for their continued trust, “We remain committed to earning it and continuing to deliver value.”